Cover Image
市場調查報告書

乾癬治療藥的全球市場:2016-2026年

Psoriasis Drugs Market Forecasts 2016-2026

出版商 Visiongain Ltd 商品編碼 281613
出版日期 內容資訊 英文 170 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
乾癬治療藥的全球市場:2016-2026年 Psoriasis Drugs Market Forecasts 2016-2026
出版日期: 2016年06月21日 內容資訊: 英文 170 Pages
簡介

乾癬治療的市場規模,預計2020年達到114億美元,到2026年更為擴大。

本報告提供全球乾癬治療藥市場現況與展望調查分析,市場概要,主要13項產品及3個有前途的治療方法的收益預測,主要11個國家市場收益預測,產業影響因素,PEST分析,及主要企業簡介等彙整結果,為您概述為以下內容。

第1章 報告概要

第2章 簡介:乾癬

  • 皮膚的理解
  • 乾癬是什麼?
  • 乾癬的原因是什麼?
  • 全球乾癬的盛行率
  • 乾癬的治療方法
  • 重病度的分類

第3章 全球乾癬用醫藥品市場

  • 全球乾癬用醫藥品市場:生物藥物壟斷收益
  • 全球乾癬用醫藥品市場:整體收益預測
  • 全球乾癬用醫藥品市場,各治療子分類:收益、市場佔有率比較
  • 全球乾癬用醫藥品市場,各治療子分類:各群組的收益預測
  • 乾癬用生技藥品:大的收益
  • 感染的局部療法:最常見的處方治療
  • 乾癬用的小分子全身療法:收益預測

第4章 主要乾癬治療藥市場

  • 主要的上市藥:取得大成功的3個治療藥
  • 主要的乾癬治療藥:收益、市場佔有率比較
  • 主要的乾癬治療藥:各群組的預測
  • Humira:來自乾癬適應症的大收益
  • Stelara:乾癬治療的強力人才
  • Enbrel:與生技仿製藥競爭
  • Remicade:市場佔有率縮小
  • Otezla:有前途的新治療藥
  • Daivobet:廣泛開立處方的局部療法
  • Soriatane:跟侵蝕銷售額的學名藥的競爭
  • Cosentyx:市場第一個IL-17抑制劑
  • Simponi:症狀的限制開發
  • Tazorac:跟學名藥的競爭
  • 開發平台的有潛力化合物

第5章 乾癬治療的主要國家市場

  • 主要國家市場:美國壟斷乾癬治療藥市場
  • 主要國家市場:收益、市場佔有率比較
  • 主要國家市場:各群組的收益預測
  • 美國:人口多、大規模的金融資源,意味對乾癬治療藥來說有大市場
  • EU主要5個國家的乾癬治療藥市場
  • 日本:第2大的國家市場
  • 中國:乾癬治療藥市場堅實擴大
  • 印度:低醫療支出抑制市場
  • 俄羅斯:市場擴大態勢
  • 巴西:推動國內廠商

第6章 乾癬:研發產品線

  • 生技藥品
  • 小分子全身療法
  • 局部療法

第7章 乾癬治療市場上主要企業

  • 主要企業
  • Johnson & Johnson
  • AbbVie
  • Amgen
  • Pfizer
  • LEO Pharma
  • Celgene
  • Novartis
  • GSK
  • Merck

第8章 乾癬治療產業的定性分析

  • 優勢、弱點
  • 機會、威脅
  • 社會,技術性,經濟及政治影響因素(PEST分析)

第9章 結論

  • 全球乾癬治療藥的市值
  • 乾癬治療藥市場主要醫藥品
  • 乾癬治療藥的主要國家市場
  • 產業的主要企業
  • 產業、市場趨勢

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0123

Psoriasis Drugs - Your Guide to R&D, Opportunities and Potential Revenues

What does the future hold for treating psoriasis? Visiongain's new report gives you multilevel revenue forecasts from 2016, helping you stay ahead in data. There you see financial results, R&D trends, opportunities and potential revenues.

In our study you examine predicted sales to 2026 at overall world market, submarket, product and national level. You also assess technologies, competitive forces and expected products. That work's purpose is to help you avoid falling behind in knowledge, missing business or losing influence.

So read on now to explore that industry and discover what its future market could be worth. See how our investigation can benefit your work.

Forecasts from 2016 to 2026 and other analyses to help you harness opportunities

Why miss data you need? Why struggle to find it? Instead let our analysis guide you through the psoriasis drug market's present and future. That understanding could bring you quicker, easier results, also benefiting your influence and reputation for business insight.

Besides revenue forecasting to 2026, our new work shows you recent results, growth rates and market shares. There you discover original analysis, seeing commercial outlooks and developments (R&D). In our 169 page study you gain 74 tables and 63 charts to benefit your research, analyses, plans, decisions and presentations.

The following sections outline what you get in our updated investigation.

Sales predictions for the world market and submarkets

What is that industry's potential? Discover in our report overall world revenue to 2026 for psoriasis-treating medicines. First you see individual revenue forecasts to 2026 for three main submarkets at world level:

  • Biological drugs
  • Topical treatments
  • Small-molecule systemic therapies.

How will those segments' revenues expand? Which classes of treatment will generate most sales? There you assess prospects for revenue growth, seeing where you can gain, assessing how that industry will compete and develop.

You find revenue predictions by product, too, seeing from 2016 how they can succeed.

Revenue predictions for 13 products to 2026 - discover what their futures hold

How will individual drugs perform from 2016 to 2026 at world level? Our report forecasts revenues of established brands and medicines expected from 2016.

image1

In our work you assess 13 drugs, including these brands:

  • Humira (adalimumab)
  • Stelara (ustekinumab)
  • Enbrel (etanercept)
  • Remicade (infliximab)
  • Otezla (apremilast)

There you discover how high sales can go, to 2026, finding drugs and years with highest predicted growth and revenues. You also examine trends and competition. You see what is happening, understanding challenges, progress, competitors and opportunities.

You find geographical revenue predictions too.

National markets - where will highest revenues and growth occur?

In developed and developing countries, opportunities in psoriasis treatment will occur from 2016. You see where and how pharma companies can develop and gain.

Our analyses show individual revenue forecasts to 2026 for these 11 national markets:

  • US and Japan
  • France, Germany, Italy, Spain and UK
  • Brazil, Russia, India and China.

There you find countries with highest revenues and potential sales growth. You assess that technology's future, seeing progress and finding what it means, including emerging trends for those skin disorder treatments.

Events affecting developers, producers and sellers - issues shaping that industry

Our report explains forces affecting that industry and market from 2016, including these influences:

  • Research and development, including monoclonal antibodies, IL-12, IL-17, IL-23, PDE4, TNF, JAK and T-cell inhibition, and histamine receptor antagonism
  • Prevalence of that skin disease, as well as issues for patients and healthcare providers - assess treatment needs
  • Competition from generic drugs, biosimilars and new biologics
  • Companies specialising in dermatology and autoimmune disorders - explore capabilities and emerging trends to treat psoriasis
  • Advances in drug delivery to benefit companies, patients and payers, including lotion, ointment and foam.

In our survey you explore political, economic, social and technological questions, assessing outlooks for business. You also examine that pharmaceutical segment's strengths, weaknesses, opportunities and threats.

That way you discover what the present and future hold, seeing what is possible for those drug developers, producers and marketers. Stay ahead in knowledge.

Companies leading that industry and our overall revenue prediction for 2020

From 2016, treatments for psoriasis hold potential for investments, medical advances and higher revenues. Our work predicts the overall world market for psoriasis medicines will reach $11.4bn in 2020, with further expansion to 2026.

See what is possible there - the expected gains. Our report shows you what technologies and firms hold greatest potential. You explore activities of these companies, among others:

  • Johnson & Johnson
  • AbbVie
  • Amgen
  • Pfizer
  • Novartis
  • Celgene
  • LEO Pharma.

Our analysis shows you participants' results, capabilities, developments and outlooks. R&D in that industry is strong. From 2016 the psoriasis market holds many opportunities for revenue growth. Our work explains that potential, helping you stay ahead in knowledge.

Main ways Psoriasis Drugs Market Forecasts 2016-2026 helps your work

In particular our new investigation gives you these advantages to benefit your research, analyses, decisions, proposals and presentations:

  • Revenues to 2026 at world level, with forecasting of 3 submarkets and 13 products - assess prospects for investments and sales growth
  • Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia - investigate leading countries for revenues and expected sales
  • Forces driving and restraining that industry's expansion - discover what influences revenue gain, finding trends, developments and opportunities
  • Prospects for established competitors and rising companies - explore companies' portfolios, results, R&D and outlooks for future success.

Information found nowhere else: see how you can gain - why miss out?

Our investigation gives you independent analysis. There you gain business intelligence found only in our work, finding where opportunities for revenue expansion exist.

See in our work how you could benefit your research, analysis and decisions. Explore progress and possibilities. Also find how you could save time and benefit your authority on those drugs, helping your reputation for commercial insight.

Medicines for psoriasis - get revenue predictions now, seeing what the future holds

Our new report is for everyone investigating drugs for inflammation and skin disorders. In our survey you explore revenue forecasts to 2026, with discussions and other data. Avoid missing out in knowledge - instead please get our report here now.

Table of Contents

1. Report Overview

  • 1.1 Psoriasis Overview
  • 1.2 Psoriasis Market Segmentation
  • 1.3 Why You Should Read this Report
  • 1.4 How this Report Delivers
  • 1.5 Main Questions Answered by this Report
  • 1.6 Who is this Report for?
  • 1.7 Research and Analysis Methods
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Some Associated Reports
  • 1.10 About Visiongain

2. Introduction to Psoriasis

  • 2.1 Understanding Skin
  • 2.2 What is Psoriasis?
  • 2.3 What Causes Psoriasis?
    • 2.3.1 Genetic Factors
    • 2.3.2 Environmental Factors
  • 2.4 World Prevalence of Psoriasis
  • 2.5 How is Psoriasis Treated?
    • 2.5.1 Biologic Drugs
    • 2.5.2 Small Molecule Systemic Drugs
    • 2.5.3 Topical Therapies
  • 2.6 Classification of Severity

3. The World Drug Market for Psoriasis 2016-2026

  • 3.1 The World Drug Market for Psoriasis in 2015: Biologic Drugs Dominate In Terms of Revenue
  • 3.2 The World Drug Market for Psoriasis: Overarching Revenue Forecast 2016-2026
  • 3.3 The World Drug Market for Psoriasis by Therapeutic Subclass: Comparison of Revenues and Market Shares to 2026
  • 3.4 The World Drug Market for Psoriasis by Therapeutic Subclass: Grouped Revenue Forecast 2016-2026
  • 3.5 Biologic Drugs for Psoriasis: Blockbuster Revenue for 2015
    • 3.5.1 Biologic Drugs for Psoriasis: Revenue Forecast, 2016-2026
  • 3.6 Topical Therapies for Psoriasis: The Most Commonly Prescribed Treatments
    • 3.6.1 Topical Therapies for Psoriasis: Revenue Forecast, 2016-2026
  • 3.7 Small Molecule Systemic Treatments for Psoriasis: A Subclass with Promise
    • 3.7.1 Small Molecule Systemic Treatments for Psoriasis: Revenue Forecast, 2016-2026

4. Leading Drugs of the Psoriasis Treatment Market, 2016-2026

  • 4.1 The Leading Drugs on the Market in 2015: Three Drugs Achieved Blockbuster Success
  • 4.2 Leading Psoriasis Drugs: Comparison of Revenues and Market Shares, 2021 and 2026
  • 4.3 Leading Psoriasis Drugs: Grouped Forecasts 2016-2026
  • 4.4 Humira: Blockbuster Revenue from Psoriasis Indications 2015
    • 4.4.1 Threat from Biosimilars
    • 4.4.2 Humira: Revenue Forecast 2016-2026
  • 4.5 Stelara: A Strong Performer in Psoriasis
    • 4.5.1 Competition for Stelara in the Pipeline
    • 4.5.2 Stelara: Revenue Forecast, 2016-2026
  • 4.6 Enbrel: Facing Competition from Biosimilars
    • 4.6.1 Sales of Enbrel in 2015
    • 4.6.2 Patent Expiries
    • 4.6.3 Threat from Biosimilars
    • 4.6.4 Enbrel: Revenue Forecast, 2016-2026
  • 4.7 Remicade: Facing a Declining Market Share
    • 4.7.1 Threat from Biosimilars
      • 4.7.1.1 Inflectra/Remsima: First Infliximab Biosimilar
      • 4.7.1.2 Flixabi: Biosimilar from Samsung Bioepis
    • 4.7.2 Remicade: Revenue Forecast, 2016-2026
  • 4.8 Otezla: A Promising New Therapy
    • 4.8.1 Otezla: Revenue Forecast, 2016-2026
  • 4.9 Daivobet: A Widely Prescribed Topical Treatment
    • 4.9.1 Daivobet: Revenue Forecast, 2016-2026
  • 4.10 Soriatane: Generic Competition Eroding Sales
    • 4.10.1 Soriatane: Revenue Forecast, 2016-2026
  • 4.11 Cosentyx: First IL-17 Inhibitor on the Market
    • 4.11.1 Cosentyx: Revenue Forecast, 2016-2026
  • 4.12 Simponi: Growth Limited by its Indications
    • 4.12.1 Simponi: Revenue Forecast, 2016-2026
  • 4.13 Tazorac: Facing Competition from Generics
    • 4.13.1 Tazorac: Revenue Forecast, 2016-2026
  • 4.14 Promising Compounds in the Pipeline
    • 4.14.1 Taltz: Second IL-17 Inhibitor to Reach the Market
    • 4.14.1.1 Taltz: Revenue Forecast 2016-2026
    • 4.14.2 Tildrakizumab: Positive Phase III Data
      • 4.14.2.1 Tildrakizumab: Revenue Forecast 2016-2026
    • 4.14.3 Guselkumab: Promising IL-23 Inhibitor
      • 4.14.3.1 Guselkumab: Revenue Forecast 2016-2026

5. Leading National Markets for Psoriasis Treatment, 2016-2026

  • 5.1 The Leading National Markets in 2015: The US Dominates the Psoriasis Market
  • 5.2 The Leading National Markets: Comparison of Revenues and Market Shares to 2026
  • 5.3 The Leading National Markets: Grouped Revenue Forecasts 2016-2026
  • 5.4 The US: Large Population and Large Financial Resources Mean There is a Large Market for Psoriasis Drugs
    • 5.4.1 The US Psoriasis Drug Market: Revenue Forecast 2016-2026
  • 5.5 The EU Psoriasis Drug Market: 2015-2026
    • 5.5.1 The Psoriasis Drug Market in Germany: Revenue Forecast 2016-2026
    • 5.5.2 The Psoriasis Drug Market in France: Revenue Forecast 2016-2026
    • 5.5.3 The Psoriasis Drug Market in the UK: Revenue Forecast 2015-2026
    • 5.5.4 The Psoriasis Drug Market in Italy: Revenue Forecast 2015-2026
    • 5.5.5 The Psoriasis Drug Market in Spain: Revenue Forecast 2015-2026
  • 5.6 Japan: The Second Largest National Market in 2015
    • 5.6.1 The Psoriasis Drug Market in Japan: Revenue Forecast 2015-2026
  • 5.7 China: The Psoriasis Drug Market is Growing Steadily
    • 5.7.1 The Psoriasis Drug Market in China: Revenue Forecast 2015-2026
  • 5.8 India: Low Healthcare Spending Limits Sales
    • 5.8.1 The Psoriasis Drug Market in India: Revenue Forecast 2015-2026
  • 5.9 Russia: Experiencing Troubled Times
    • 5.9.1 The Psoriasis Drug Market in Russia: Revenue Forecast 2015-2026
  • 5.10 Brazil: Encouraging Domestic Manufacturers
    • 5.10.1 The Psoriasis Drug Market in Brazil: Revenue Forecast 2015-2026

6. Psoriasis R&D Pipeline, 2016

  • 6.1 Biologics
    • 6.1.1 Brodalumab: Less Promising Than Expected
    • 6.1.2 BI 655066: First IL-23 to Reach the Market?
    • 6.1.3 Cimzia: Potential Licence Expansion to Psoriasis
    • 6.1.4 Orencia: Efficacy in Psoriasis and Psoriatic Arthritis?
    • 6.1.5 ABT-122: A Dual Action Molecule
    • 6.1.6 Namilumab: Novel Mechanism of Action
    • 6.1.7 Biosimilars: The Growing Threat to Biologics
  • 6.2 Small Molecule Systemic Treatments
    • 6.2.1 Xeljanz: Approval in the Balance
    • 6.2.2 CF-101: Efficacy in Question
    • 6.2.3 Baricitinib: Janus Kinase Inhibitor
    • 6.2.4 JNJ 168: Histamine Receptor Antagonist
    • 6.2.5 Prurisol: Will its Phase II Study Succeed?
  • 6.3 Topical Molecules
    • 6.3.1 IDP-118 Lotion: Combines Steroid and Retinoid
    • 6.3.2 M518101 Ointment: Phosphodiesterase Inhibitor
    • 6.3.3 122-0551 Foam: Steroid-Based Product

7. Leading Companies in the Psoriasis Drug Market, 2016

  • 7.1 The Leading Companies in the Market
  • 7.2 Johnson & Johnson: Top Performer in Psoriasis
  • 7.3 AbbVie: Highly Reliant on Humira
  • 7.4 Amgen: Actively Developing Biosimilars
  • 7.5 Pfizer: Hospira Acquisition Boosts Biosimilar Portfolio
  • 7.6 LEO Pharma: Specialises in Dermatology
  • 7.7 Celgene: Sales Boosted by Otezla
  • 7.8 Novartis: Cosentyx Performing Well
  • 7.9 GSK: Looking to Expand Their Immunology Portfolio
  • 7.10 Merck: A Limited Share of the Market

8. Qualitative Analysis of the Psoriasis Market, 2016-2026

  • 8.1 Strengths and Weaknesses of the Psoriasis Drug Market, 2016-2026
    • 8.1.1 Strengths of High Patient Demand, Active Research and High Revenue Potential
    • 8.1.2 Weaknesses from Shortcomings of Current Treatments and Patent Expiries
  • 8.2 The Opportunities and Threats Facing the Psoriasis Drug Market, 2016-2026
    • 8.2.1 Opportunities of Patient Demand for Improved Treatments
    • 8.2.2 Threats from Financial Restrictions and Market Saturation
  • 8.3 Social, Technological, Economic and Political Factors Influencing the Psoriasis Drug Market (STEP analysis), 2016-2026
    • 8.3.1 Social Factors Influencing the Market
    • 8.3.2 Technological Factors Affecting the Psoriasis Drug Market
    • 8.3.3 Economic Impact of Psoriasis Treatment
    • 8.3.4 Political Considerations Influencing Drug Approval
      • 8.3.4.1 Biosimilar Approval in Developed Countries
      • 8.3.4.2 Biosimilar Approval in Developing Countries

9. Conclusions

  • 9.1 The World Market Value for Psoriasis Drugs, 2016-2026
  • 9.2 Leading Drugs of the Psoriasis Treatment Market, 2016-2026
  • 9.3 Leading National Markets for Psoriasis Drugs, 2016-2026
  • 9.4 Leading Companies in the Market
  • 9.5 Trends in the Psoriasis Drugs Market

List of Tables

  • Table 2.1 Biologic Drugs Indicated for the Treatment of Psoriasis, 2016
  • Table 2.2 Small Molecule Systemic Drugs Indicated for the Treatment of Psoriasis, 2016
  • Table 2.3 Topical Treatments Indicated for the Treatment of Psoriasis, 2016
  • Table 3.1 The Psoriasis Drug Market by Therapeutic Class: Revenue ($m) and Market Share (%), 2015
  • Table 3.2 The World Drug Market for Psoriasis: Revenue Forecast ($m), 2015-2026
  • Table 3.3 The World Drug Market for Psoriasis by Therapeutic Subclass: Revenue ($m) and Market Share (%) Predictions, 2021 and 2026
  • Table 3.4 The World Drug Market for Psoriasis by Therapeutic Subclass: Revenue Forecasts ($m), 2015-2026
  • Table 3.5 Biologic Drugs for Psoriasis: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 3.6 Topical Treatments for Psoriasis: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 3.7 Small Molecule Systemic Treatments for Psoriasis: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 4.1 The Top Ten Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2015
  • Table 4.2 Leading Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2021 and 2026
  • Table 4.3 Leading Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2015-2021
  • Table 4.4 Leading Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2022-2026
  • Table 4.5 Humira: Key Facts
  • Table 4.6 Humira: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.7 Stelara: Key Facts
  • Table 4.8 Stelara: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.9 Enbrel: Key Facts
  • Table 4.10 Enbrel: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.11 Remicade: Key Facts
  • Table 4.12 Remicade: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.13 Otezla: Key Facts
  • Table 4.14 Otezla: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.15 Daivobet: Key Facts
  • Table 4.16 Daivobet: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.17 Soriatane: Key Facts
  • Table 4.18 Soriatane: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.19 Cosentyx: Key Facts
  • Table 4.20 Cosentyx: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.21 Simponi: Key Facts
  • Table 4.22 Simponi: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.23 Tazorac: Key Facts
  • Table 4.24 Tazorac: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.25 Taltz: Key Facts
  • Table 4.26 Taltz: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.27 Tildrakizumab: Key Facts
  • Table 4.28 Tildrakizumab: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 4.29 Guselkumab: Key Facts
  • Table 4.30 Guselkumab: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.1 The Leading National Markets for Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2015
  • Table 5.2 The Leading National Markets for Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2021 and 2026
  • Table 5.3 The Leading National Markets for Psoriasis Drugs: Grouped Revenue Forecasts ($m), 2015-2021
  • Table 5.4 The Leading National Markets for Psoriasis Drugs: Grouped Revenue Forecasts ($m), 2022-2026
  • Table 5.5 The US Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.6 The EU5 Psoriasis Drug Markets: Grouped Revenue Forecasts ($m), 2015-2026
  • Table 5.7 The German Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2015-2026
  • Table 5.8 The French Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 5.9 The Psoriasis Drug Market in the UK: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 5.10 The Psoriasis Drug Market in Italy: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 5.11 The Psoriasis Drug Market in Spain: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 5.12 The Psoriasis Drug Market in Japan: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 5.13 The Psoriasis Drug Market in China: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 5.14 The Psoriasis Drug Market in India: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 5.15 The Psoriasis Drug Market in Russia: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 5.16 The Psoriasis Drug Market in Brazil: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
  • Table 6.1 Biologic Drugs in the Pipeline for Psoriasis and Psoriatic Arthritis, 2016
  • Table 6.2 Biosimilar Drugs in Development
  • Table 6.3 Small Molecule Systemic Drugs in the Pipeline for Psoriasis and Psoriatic Arthritis, 2016
  • Table 6.4 Topical Treatments in the Pipeline for Psoriasis and Psoriatic Arthritis, 2016
  • Table 7.1 The Leading Companies in the Psoriasis Drug Market: Revenue ($m) and Market Share (%), 2015
  • Table 7.2 J&J: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
  • Table 7.3 AbbVie: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
  • Table 7.4 Amgen: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
  • Table 7.5 Pfizer: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
  • Table 7.6 Leo Pharma: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
  • Table 7.7 Celgene: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
  • Table 7.8 Novartis: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
  • Table 7.9 GSK: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
  • Table 7.10 Merck: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
  • Table 8.1 Strengths and Weaknesses of the Psoriasis Drug Market, 2016-2026
  • Table 8.2 Opportunities and Threats Facing the Psoriasis Drug Market, 2016-2026
  • Table 8.3 Social, Technological, Economic and Political Factors Influencing the Psoriasis Drug Market (STEP analysis), 2016-2026
  • Table 9.1 Drivers and Restraints of the Psoriasis Drug Market, 2016-2026

List of Figures

  • Figure 1.1 Main Segments and Sub-Segments of the Psoriasis Market, 2016
  • Figure 3.1 The Psoriasis Drug Market by Therapeutic Class: Market Shares (%), 2015
  • Figure 3.2 The World Drug Market for Psoriasis: Revenue Forecast ($m), 2015-2026
  • Figure 3.3 The World Drug Market for Psoriasis by Therapeutic Subclass: Market Shares (%), 2021
  • Figure 3.4 The World Drug Market for Psoriasis by Therapeutic Subclass: Market Shares (%), 2026
  • Figure 3.5 Biologic Drugs: Share (%) of the Psoriasis Market, 2015
  • Figure 3.6 Biologic Drugs for Psoriasis: Revenue Forecast ($m), 2015-2026
  • Figure 3.7 Topical Treatments: Share (%) of the Psoriasis Market, 2015
  • Figure 3.8 Topical Treatments for Psoriasis: Revenue Forecast ($m), 2015-2026
  • Figure 3.9 Small Molecule Systemic Treatments: Share (%) of the Psoriasis Market, 2015
  • Figure 3.10 Small Molecule Systemic Treatments: Revenue ($m) Forecast, 2015-2026
  • Figure 4.1 The Leading Psoriasis Drugs: Market Shares (%), 2015
  • Figure 4.2 The Leading Psoriasis Drugs: Market Shares (%), 2021
  • Figure 4.3 The Leading Psoriasis Drugs: Market Shares (%), 2026
  • Figure 4.4 Humira Revenue Forecast ($m), 2015-2026
  • Figure 4.5 Stelara Revenue Forecast ($m), 2015-2026
  • Figure 4.6 Enbrel Revenue Forecast ($m), 2015-2026
  • Figure 4.7 Remicade Revenue Forecast ($m), 2015-2026
  • Figure 4.8 Otezla: Revenue Forecast ($m), 2015-2026
  • Figure 4.9 Daivobet: Revenue Forecast ($m), 2015-2026
  • Figure 4.10 Soriatane Revenue Forecast ($m), 2015-2026
  • Figure 4.11 Cosentyx Revenue Forecast ($m), 2015-2026
  • Figure 4.12 Simponi Revenue Forecast ($m), 2015-2026
  • Figure 4.13 Tazorac Revenue Forecast ($m), 2015-2026
  • Figure 4.14 Taltz: Revenue Forecast ($m), 2015-2026
  • Figure 4.15 Tildrakizumab: Revenue Forecast ($m), 2015-2026
  • Figure 4.16 Guselkumab: Revenue Forecast ($m), 2015-2026
  • Figure 5.1 The Leading National Markets for Psoriasis Drugs: Market Shares (%), 2015
  • Figure 5.2 The Leading National Markets for Psoriasis Drugs: Market Shares (%), 2021
  • Figure 5.3 The Leading National Markets for Psoriasis Drugs: Market Shares (%), 2026
  • Figure 5.4 The US Psoriasis Drug Market: World Market Share (%), 2015
  • Figure 5.5 The US Psoriasis Drug Market: Revenue Forecast ($m), 2015-2026
  • Figure 5.6 The EU5 Psoriasis Drug Market: World Market Share (%), 2015
  • Figure 5.7 The EU5 Psoriasis Drug Market: Revenue Forecast ($m), 2015-2026
  • Figure 5.8 The German Psoriasis Drug Market: Revenue Forecast ($m), 2015-2026
  • Figure 5.9 The French Psoriasis Drug Market: Revenue Forecast ($m), 2015-2026
  • Figure 5.10 The UK Psoriasis Drug Market: Revenue Forecast ($m), 2015-2026
  • Figure 5.11 The Psoriasis Drug Market in Italy: Revenue Forecast ($m), 2015-2026
  • Figure 5.12 The Psoriasis Drug Market in Spain: Revenue Forecast ($m), 2015-2026
  • Figure 5.13 The Psoriasis Drug Market in Japan: World Market Share (%), 2015
  • Figure 5.14 The Psoriasis Drug Market in Japan: Revenue Forecast ($m), 2015-2026
  • Figure 5.15 The Psoriasis Drug Market in China: World Market Share (%), 2015
  • Figure 5.16 The Psoriasis Drug Market in China: Revenue Forecast ($m), 2015-2026
  • Figure 5.17 The Psoriasis Drug Market in India: World Market Share (%), 2015
  • Figure 5.18 The Psoriasis Drug Market in India: Revenue Forecast ($m), 2015-2026
  • Figure 5.19 The Psoriasis Drug Market in Russia: World Market Share (%), 2015
  • Figure 5.20 The Psoriasis Drug Market in Russia: Revenue Forecast ($m), 2015-2026
  • Figure 5.21 The Psoriasis Drug Market in Brazil: World Market Share (%), 2015
  • Figure 5.22 The Psoriasis Drug Market in Brazil: Revenue Forecast ($m), 2015-2026
  • Figure 7.1 The Leading Companies in the Psoriasis Drug Market: Market Shares (%), 2015
  • Figure 7.2 J&J: Breakdown of Revenue by Indication (%), 2015
  • Figure 7.3 AbbVie: Breakdown of Revenue by Indication (%), 2015
  • Figure 7.4 Amgen: Breakdown of Revenue by Indication (%), 2015
  • Figure 7.5 Pfizer: Breakdown of Revenue by Indication (%), 2015
  • Figure 7.6 Leo Pharma: Breakdown of Revenue by Indication (%), 2015
  • Figure 7.7 Celgene: Breakdown of Revenue by Indication (%), 2015
  • Figure 7.8 Novartis: Breakdown of Revenue by Indication (%), 2015
  • Figure 7.9 GSK: Breakdown of Revenue by Indication (%), 2015
  • Figure 7.10 Merck: Breakdown of Revenue by Indication (%), 2015
  • Figure 9.1 The World Market for Psoriasis Drugs by Therapeutic Category ($m), 2016-2026
  • Figure 9.2 The Leading Drugs of the Psoriasis Drug Market: Comparison of Revenue ($m), 2016, 2021 and 2026
  • Figure 9.3 The Leading National Markets: Comparison of Revenue ($m), 2016, 2021 and 2026
  • Figure 9.4 The Leading Companies in the Market: Comparison of Revenue Generated by Sales of Drugs for Psoriasis ($m), 2015

Companies Listed

  • Abbott Laboratories
  • AbbVie Inc
  • Alcon
  • Allergan, PLC
  • Amgen
  • AstraZeneca (AZ)
  • Biogen Inc
  • Boehringer Ingelheim
  • Brazilian Ministry of Health
  • Bristol-Myers Squibb (BMS)
  • Can-Fite BioPharma
  • Celgene Corporation
  • Cellceutix Corporation
  • Celltrion
  • Center for Drug Evaluation (China)
  • Centocor Ortho Biotech Inc
  • Cipla Ltd
  • Coherus BioSciences
  • Committee for Medicinal Products for Human Use (CHMP)
  • Daiichi Sankyo Co Ltd
  • Dermira
  • Eisai Co Ltd
  • Eli Lilly and Company
  • European Medicines Agency (EMA)
  • Epirus Biopharmaceuticals
  • European Union (EU)
  • Food and Drug Administration (FDA)
  • G & W Laboratories
  • Glaxo Wellcome
  • GlaxoSmithKline (GSK)
  • Hospira
  • Immunex Corporation
  • Incyte Corporation
  • Janssen Biotech Inc
  • Janssen Pharmaceutical Companies
  • Japanese Ministry of Health, Labour and Welfare
  • Johnson & Johnson (J&J)
  • Kyowa Hakko Kirin Co Ltd
  • LEO Pharma A/S
  • Maruho Co Ltd
  • Merck & Co Inc
  • Merck Sharp & Dohme (MSD)
  • Mitsubishi Tanabe Pharma Corporation
  • Momenta Pharmaceuticals Inc
  • MorphoSys AG
  • Mylan
  • Nippon Kayaku Co Ltd
  • Novartis International AG
  • Pfizer Inc
  • Ranbaxy Laboratories Ltd
  • Samsung Bioepis
  • Sandoz
  • Sanofi SA
  • Servier Laboratories
  • Shanghai CP Guojian Pharmaceutical Co. Ltd
  • Sistema Único de Saúde (SUS)
  • SmithKline Beecham
  • South Korean Ministry of Food and Drug Safety
  • Stiefel Laboratories
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Co Ltd
  • Teva Pharmaceutical Industries Ltd
  • Therapeutics Inc
  • UCB
  • Valeant Pharmaceuticals International Inc
  • World Bank
  • Wyeth
  • Zydus Cadila
Back to Top